| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.
|
J Clin Oncol
|
2003
|
6.66
|
|
2
|
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
|
Lancet
|
2009
|
5.82
|
|
3
|
National Institutes of Health State-of-the-Science Conference Statement: Symptom Management in Cancer: Pain, Depression, and Fatigue, July 15-17, 2002.
|
J Natl Cancer Inst
|
2003
|
2.99
|
|
4
|
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.
|
J Clin Oncol
|
2012
|
2.15
|
|
5
|
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.
|
J Clin Oncol
|
2002
|
2.07
|
|
6
|
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.
|
Int J Radiat Oncol Biol Phys
|
2004
|
1.83
|
|
7
|
National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002.
|
J Natl Cancer Inst Monogr
|
2004
|
1.70
|
|
8
|
Creeping phase II-ism and the medical pharmaceutical complex: weapons of mass distraction in the war against lung cancer.
|
J Clin Oncol
|
2005
|
1.39
|
|
9
|
Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis.
|
J Thorac Oncol
|
2006
|
1.38
|
|
10
|
Small cell lung cancer: state of the art and future perspectives.
|
Lung Cancer
|
2004
|
1.37
|
|
11
|
A review of first-line treatment for small-cell lung cancer.
|
J Thorac Oncol
|
2006
|
1.32
|
|
12
|
Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected].
|
J Mol Diagn
|
2003
|
1.20
|
|
13
|
Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).
|
Chest
|
2007
|
1.13
|
|
14
|
Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904.
|
J Clin Oncol
|
2009
|
1.10
|
|
15
|
Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes.
|
Jpn J Radiol
|
2010
|
0.91
|
|
16
|
Outcome of radiation therapy for renal transplant rejection refractory to chemical immunosuppression.
|
Radiother Oncol
|
2005
|
0.91
|
|
17
|
Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer.
|
Radiother Oncol
|
2002
|
0.87
|
|
18
|
Docetaxel-based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer.
|
Oncologist
|
2003
|
0.85
|
|
19
|
Locally advanced esophageal cancer.
|
Curr Treat Options Oncol
|
2002
|
0.84
|
|
20
|
Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer.
|
J Natl Cancer Inst
|
2007
|
0.80
|
|
21
|
Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).
|
Clin Lung Cancer
|
2002
|
0.80
|
|
22
|
Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003.
|
Am J Clin Oncol
|
2003
|
0.76
|
|
23
|
Recall those thrilling days of yesteryear ...
|
Oncologist
|
2010
|
0.75
|
|
24
|
Limited-disease small-cell lung cancer research: sense and nonsense.
|
Int J Radiat Oncol Biol Phys
|
2004
|
0.75
|
|
25
|
The thrill of victory; the agony of defeat.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.75
|